Affirm's Bed Bath & Beyond Partnership Adds Volume, but Valuation and Risks Persist

What happened

Affirm announced a partnership with Bed Bath & Beyond to offer BNPL options, potentially driving higher merchant growth and transaction volumes. However, the DeepValue master report maintains a 'POTENTIAL SELL' rating, citing a DCF intrinsic value of ~$24 per share against a market price of ~$73—a >200% premium. The company's business is improving, with GAAP profitability and strong FCF, but the balance sheet remains leveraged (Net Debt/EBITDA ~9x, interest coverage ~0.3x) and the sector faces elevated delinquencies and regulatory uncertainty. This partnership is a positive but incremental development that does not materially alter the risk/reward calculus.

Implication

The Bed Bath & Beyond deal expands Affirm's merchant network and should support GMV growth, but it does little to address the core investment concerns: extreme valuation (104x P/E), high leverage, and exposure to credit and regulatory risks. Until the stock price converges closer to intrinsic value or the balance sheet materially de-risks, the risk/reward remains unfavorable for long-term investors. Any positive news like this partnership should be used as an exit opportunity for holders.

Thesis delta

The Bed Bath & Beyond partnership is a modest positive for Affirm's growth narrative, but it does not shift the fundamental thesis. The stock remains overvalued relative to intrinsic value, and the company's leveraged balance sheet and sector risks persist. The partnership is incremental, not transformative, and does not alter the POTENTIAL SELL stance.